- Trials with a EudraCT protocol (49)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
49 result(s) found for: Natural Killer Cell.
Displaying page 1 of 3.
EudraCT Number: 2012-000054-63 | Sponsor Protocol Number: HNJ-NKAES-2012 | Start Date*: 2012-07-25 |
Sponsor Name:FUNDACION INVESTIGACION BIOMEDICA HOSPITAL NINO JESUS | ||
Full Title: Salvage therapy with chemotherapy and Natural Killer cells in relapsed/refractory paediatric T cell lymphoblastic leukaemia and lymphoma. | ||
Medical condition: Relapsed/refractory paediatric T cell lymphoblastic leukaemia and lymphoma. | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2012-000411-91 | Sponsor Protocol Number: NKZellen-Version1.0 | Start Date*: 2013-02-13 |
Sponsor Name:Charité - Universitätsmedizin Berlin | ||
Full Title: Monitoring natural killer cells in multiple sclerosis patients treated with fingolimod: a monocentric, prospective, one year, baseline-to-treatment, open-label, single group pilot trial | ||
Medical condition: relapsing-remitting multiple sclerosis | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-001929-27 | Sponsor Protocol Number: NK4AML | Start Date*: 2020-05-20 |
Sponsor Name:Radboud University Medical Centre | ||
Full Title: Infusion of ex vivo-generated allogeneic natural killer cells in combination with subcutaneous IL-2 in patients with acute myeloid leukemia: a phase I/IIa study’ | ||
Medical condition: AML patients who do not have rapid progressive disease with or without disease controlling medication and who are not eligible for allogeneic SCT. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2013-003421-28 | Sponsor Protocol Number: TUD-HINKL1-059 | Start Date*: 2014-07-10 | |||||||||||
Sponsor Name:Technische Universität Dreden | |||||||||||||
Full Title: Randomised controlled phase-2 trial to determine the efficacy of adoptive immunotherapy with haploidentical natural killer cells in high-risk acute myeloid leukemia | |||||||||||||
Medical condition: Newly diagnosed high-risk AML other than acute promyelocytic leukemia, ≥20% blasts | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-002130-30 | Sponsor Protocol Number: NSCLC-TKD/IL-2 | Start Date*: 2013-11-15 | |||||||||||
Sponsor Name:Technische Universität München Fakultät für Medizin | |||||||||||||
Full Title: Targeted Natural Killer (NK) cell based adoptive immunotherapy for the treatment of patients with Non-Small Cell Lung Cancer (NSCLC) after radiochemotherapy (RCT) | |||||||||||||
Medical condition: Interventional phase II clinical trial incorporating a parallel control group of patients receiving no adjuvant immunotherapy. Patients with non small lung cell carcinoma (NSCLC) in stage III A and... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001396-69 | Sponsor Protocol Number: KO-TIP-002 | Start Date*: 2016-10-27 |
Sponsor Name:Kura Oncology Inc., | ||
Full Title: An Open Label Phase II Study of Tipifarnib in Subjects with Relapsed or Refractory Peripheral T-Cell LymphomaLymphoma | ||
Medical condition: Subjects with Relapses and Refractory Peripheral T-Cell Lymphoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: View results |
EudraCT Number: 2014-000709-10 | Sponsor Protocol Number: UKM12_0026 | Start Date*: 2014-12-19 | |||||||||||
Sponsor Name:Universitätsklinikum Münster | |||||||||||||
Full Title: Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential | |||||||||||||
Medical condition: relapsing-remitting multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004983-23 | Sponsor Protocol Number: 201900874 | Start Date*: 2021-01-18 |
Sponsor Name:University Medical Center Groningen | ||
Full Title: Bioequivalence study of prednisolone and dexamethasone: corticosteroids revisited | ||
Medical condition: This study does not investigate a medical condition and is performed in healthy volunteers. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-001371-20 | Sponsor Protocol Number: 18-PP-03 | Start Date*: 2018-06-11 | |||||||||||
Sponsor Name:CHU de Nice | |||||||||||||
Full Title: Study of the role of local treatments on the modulation of the microbiome in psoriatic skin | |||||||||||||
Medical condition: Psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001690-16 | Sponsor Protocol Number: BORTEM-17 | Start Date*: 2018-05-29 |
Sponsor Name:Helse Bergen HF | ||
Full Title: Bortezomib sensitization of recurrent glioblastoma with unmethylated MGMT promoter to Temozolomide phase 1B/II study | ||
Medical condition: recurrent or progressed WHO grade IV intracranial glioblastoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NO (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2015-001901-15 | Sponsor Protocol Number: NKCell_LMA_2015 | Start Date*: 2016-04-01 | |||||||||||
Sponsor Name:Antonio Pérez Martínez | |||||||||||||
Full Title: Natural Killer cell infusion as consolidation therapy in children and adolescents with acute myelogenous leukemia. | |||||||||||||
Medical condition: Acute myeloid leukemia | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-002811-29 | Sponsor Protocol Number: PDX-008 | Start Date*: 2006-11-10 |
Sponsor Name:Allos Therapeutics, Inc. | ||
Full Title: A Multi-center Phase 2 Open-label Study of (RS)-10-Propargyl-10-Deazaaminopterin (pralatrexate) with Vitamin B12 and Folic Acid Supplementation in Patients with Relapsed or Refractory Peripheral T-... | ||
Medical condition: Phase 2 Open-label Study of (RS)-10-Propargyl-10-Deazaaminopterin (pralatrexate) with Vitamin B12 and Folic Acid Supplementation in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) IT (Completed) GB (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2011-003181-32 | Sponsor Protocol Number: CIMNK1001 | Start Date*: 2011-10-14 | ||||||||||||||||
Sponsor Name:Karolinska University Hospital | ||||||||||||||||||
Full Title: In vivo expansion and efficacy of adoptive natural killer cell-based immunotherapy for high-risk myeloid diseases | ||||||||||||||||||
Medical condition: acute myeloid leukemia and myelodysplastic syndrome | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: SE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-000704-28 | Sponsor Protocol Number: GCP#05.01.020 | Start Date*: 2016-06-16 | ||||||||||||||||||||||||||
Sponsor Name:Gamida Cell Ltd | ||||||||||||||||||||||||||||
Full Title: A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord®, Ex Vivo Expanded, Umbilical Cord Blood-derived, Stem and Progenitor Cells, versus Unmanipulated Umbilical Cord... | ||||||||||||||||||||||||||||
Medical condition: High risk haematological malignancies | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: ES (Ongoing) NL (Ongoing) GB (GB - no longer in EU/EEA) IT (Prematurely Ended) PT (Completed) FR (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2010-022230-81 | Sponsor Protocol Number: PDX-017 | Start Date*: 2011-04-05 | |||||||||||
Sponsor Name:Allos Therapeutics, Inc. | |||||||||||||
Full Title: A Multi-center, Randomized, Phase 3 Study of Sequential Pralatrexate Versus Observation in Patients with Previously Undiagnosed Peripheral T-cell Lymphoma Who Have Achieved an Objective Response Fo... | |||||||||||||
Medical condition: Patients with previously undiagnosed peripheral T-cell lymphoma who have achieved an objective response following initial treatment with CHOP-based chemotherapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) CZ (Completed) IE (Completed) ES (Completed) BE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002659-41 | Sponsor Protocol Number: MOR208C201 | Start Date*: 2012-12-17 | |||||||||||
Sponsor Name:MorphoSys AG | |||||||||||||
Full Title: A Phase IIa, Open-Label, Multicenter Study of Single-Agent MOR00208, an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma | |||||||||||||
Medical condition: Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) IT (Completed) HU (Ongoing) ES (Completed) DE (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003686-17 | Sponsor Protocol Number: WiNK | Start Date*: 2020-07-03 | |||||||||||
Sponsor Name:Glycostem Therapeutics BV | |||||||||||||
Full Title: A prospective Phase I/IIa, open-label, multicenter trial to evaluate the safety and efficacy of oNKord®, an off-the-shelf, ex vivo-cultured allogeneic NK cell preparation, in subjects with acute my... | |||||||||||||
Medical condition: acute myeloid leukaemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Ongoing) DE (Ongoing) FR (Ongoing) NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001282-17 | Sponsor Protocol Number: E7389-G000-223 | Start Date*: 2018-03-23 |
Sponsor Name:Eisai Inc. | ||
Full Title: A Phase 2, Multicenter, Open-label Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma S... | ||
Medical condition: Relapsed/Refractory Rhabdomyosarcoma Non-rhabdomyosarcoma Soft Tissue Sarcoma Ewing Sarcoma | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2019-004541-33 | Sponsor Protocol Number: immvzmpr1 | Start Date*: Information not available in EudraCT |
Sponsor Name:Västra Götalandsregionen | ||
Full Title: A clinical study to examine cellular and humoral immunity against measles and chickenpox in children and adolescents 0-18 years in childhood cancer. | ||
Medical condition: This study will be conducted as a longitudinal study. Former studies have shown that immunity is affected after treatment against childhood cancer. We want to investigate humoral and cell-mediated ... | ||
Disease: | ||
Population Age: Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2017-005130-27 | Sponsor Protocol Number: IVORY | Start Date*: 2019-11-08 | |||||||||||
Sponsor Name:Cambridge University Hospitals NHS Foundation Trust and University of Cambridge | |||||||||||||
Full Title: Low-dose interleukin-2 for the reduction of vascular inflammation in Acute Coronary Syndromes (IVORY) | |||||||||||||
Medical condition: Acute Coronary Syndrome (ACS) such as myocardial infarction and unstable angina | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.